Ahra Cho, MD
Internal Medicine · Los Angeles, CANPI 1902051659
Payments from drug & device makers
Across 462 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$1K
- Lilly USA, LLC$739
- IBSA Pharma Inc.$628
- Novo Nordisk$570
- AstraZeneca$560
- plus $5K from 34 others
What the payments were for
- Food & beverage$9,445100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $1,225 |
| Amgen | 59 | $1,110 |
| Lilly USA, LLC | 35 | $739 |
| IBSA Pharma Inc. | 58 | $628 |
| Novo Nordisk | 30 | $570 |
| AstraZeneca | 25 | $560 |
| Nestle Healthcare Nutrition Inc. | 23 | $479 |
| Amarin Pharma, Inc. | 18 | $417 |
| Sunovion Pharmaceuticals Inc. | 22 | $402 |
| Ironwood Pharmaceuticals, Inc | 15 | $358 |
| Sumitomo Pharma America, Inc. | 12 | $268 |
| Aimmune Therapeutics, Inc. | 9 | $253 |
| Boehringer Ingelheim | 10 | $236 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $232 |
| Bayer | 10 | $212 |
| Novartis | 10 | $180 |
| Stryker | 1 | $170 |
| Lundbeck LLC | 6 | $151 |
| Celltrion, Inc. | 1 | $145 |
| Scilex Pharmaceuticals Inc. | 7 | $129 |
| Pfizer | 4 | $113 |
| Esperion Therapeutics, Inc. | 4 | $100 |
| Vivus LLC | 4 | $83 |
| Dexcom, Inc. | 4 | $79 |
| GSK | 3 | $64 |
| Eisai Inc. | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 2 | $55 |
| Biogen | 2 | $50 |
| Astellas Pharma US Inc | 2 | $49 |
| Exact Sciences | 2 | $49 |
| Genentech USA, Inc. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Dentsply Sirona Inc | 2 | $29 |
| Abbott | 1 | $28 |
| Merck | 1 | $28 |
| Insmed, Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Shield Therapeutics Inc | 1 | $23 |
| Almatica Pharma LLC | 1 | $22 |
| Smith+Nephew | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,445 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 272 | $232,905 |
| CreonLipase/Protease/Amylase | 139 | $175,446 |
| JanuviaSitagliptin Phosphate | 107 | $106,986 |
| FarxigaDapagliflozin Propanediol | 80 | $77,794 |
| VascepaIcosapent Ethyl | 139 | $57,897 |
| OzempicSemaglutide | 58 | $56,484 |
| Diclofenac Epolamine | 86 | $42,685 |
| DapagliflozinDapagliflozin Propanediol | 44 | $40,380 |
| TrulicityDulaglutide | 28 | $37,928 |
| EliquisApixaban | 34 | $32,265 |
| LinzessLinaclotide | 52 | $29,837 |
| ZenpepLipase/Protease/Amylase | 23 | $27,699 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $25,647 |
| TradjentaLinagliptin | 26 | $23,429 |
| Memantine Hcl ErMemantine Hcl | 93 | $22,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $236 | $256,334298 claims |
| AbbVieCreon, Linzess, Restasis | $1,225 | $216,696207 claims |
| MerckJanuvia, Janumet | $28 | $132,632139 claims |
| AstraZenecaFarxiga | $560 | $77,79480 claims |
| Novo NordiskOzempic, Rybelsus | $570 | $74,20871 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $739 | $53,54543 claims |
| PfizerEliquis | $113 | $32,26534 claims |
| Aimmune Therapeutics, Inc.Zenpep | $253 | $27,69923 claims |
| AmgenProlia | $1,110 | $21,99213 claims |
| GSKShingrix | $64 | $10,58452 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $129 | $9,71914 claims |
| Eisai Inc.Dayvigo | $62 | $3,72111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.